The World Health Organization (WHO) has unveiled its updated Bacterial Priority Pathogens List (BPPL) for 2024, highlighting 15 families of antibiotic-resistant bacteria grouped into critical, high, and medium categories for…
BioNTech SE (Nasdaq: BNTX), referred to as “BioNTech” or the “Company,” held its Annual General Meeting (AGM) on May 17, 2024. The virtual assembly saw representation from 87.51% of the…
AbbVie (NYSE: ABBV) announced it will present 15 abstracts at the 2024 Digestive Disease Week (DDW) Annual Meeting, occurring May 18-21 in Washington, D.C., and virtually. “At DDW, AbbVie is…
Irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) are often confused, as their names and symptoms—such as diarrhea and abdominal pain—are similar. However, these gastrointestinal (GI) disorders are fundamentally…
Eli Lilly and Company (NYSE: LLY) announced positive topline results from the QWINT-2 and QWINT-4 phase 3 clinical trials for once-weekly insulin efsitora alfa (efsitora) in adults with type 2…
A spatial AI biomarker company specializing in deciphering cellular conversations and mapping cellular interactions within tissue samples to predict therapeutic outcomes has announced the expansion of its executive leadership team.…
Accenture Ventures, a strategic arm of Accenture (NYSE: ACN), recently announced its investment in Turbine, a forward-thinking predictive simulation company dedicated to interpreting human biology. This investment aims to bolster…
Genentech, a member of the Roche Group, disclosed favorable outcomes from the Phase Ib clinical trial of CT-388, a dual GLP-1/GIP receptor agonist aimed at addressing obesity and type 2…
SunLink Health Systems, Inc. (NYSE American: SSY) disclosed today a loss from continuing operations of $824,000 (equating to a loss of $0.12 per fully diluted share) for its third fiscal…
OmniAb has announced its participation in the 20th Annual PEGS Boston – The Essential Protein & Antibody Engineering Summit, held at the Omni Hotel. Earlier today, the company presented an…
enGene Holdings Inc. (Nasdaq: ENGN), a clinical-stage genetic medicines company with its lead non-viral program EG-70 undergoing pivotal trials for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), announced the election of…
Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders such as…